Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Stage 0 Oropharyngeal Squamous Cell Carcinoma

Known as: Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharynx Epidermoid Carcinoma in situ, Stage 0 Oropharynx Squamous Cell Carcinoma 
Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PURPOSE Oropharynx cancers associated with human papillomavirus (HPV) have a favorable prognosis, but current treatment… Expand
2018
2018
Purpose To investigate the effect of adding concurrent chemotherapy (CT) to cetuximab plus radiotherapy (RT; CT-cetux-RT… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2017
2017
INTRODUCTION Molecular studies about carcinomas of the oral cavity and oropharynx demonstrate the presence of human papilomavirus… Expand
2017
2017
ZusammenfassungPlattenepithelkarzinome der Kopf-Hals-Region (HNSCC) sind nach wie vor eine therapeutische Herausforderung. Auch… Expand
2016
2016
Background p16 has been indicated as a suitable surrogate biomarker of HPV infection. The prognosis of p16-positive oropharynx… Expand
  • figure 2
  • figure 1
  • table IV
  • figure 4
  • figure 3
2010
2010
This editorial discusses the Pulte and Brenner article on the recent survival trend observed in patients with squamous cell… Expand
2002
2002
Tumour cell proliferation is an important biological prognostic parameter to be considered alongside clinical and… Expand
1998
1998
Fifty-five patients with resectable and unresectable oropharynx carcinomas were treated with concomitant boost radiotherapy… Expand
  • table 2
  • figure 1
1990
1990
Induction chemotherapy (CT) has demonstrated overall response rates of 80% for oropharynx carcinomas, but no overall survival… Expand
1988
1988
Induction chemotherapy in oropharynx carcinomas had demonstrated overall response rates of 80%, but no overall survival benefit… Expand